Biologics and biosimilars in musculoskeletal diseases: addressing regulatory inconsistencies and clinical uncertainty

Abstract

Biologics are complex protein-based medications derived from living organisms, used primarily to treat immune-related diseases. Unlike small-molecule drugs synthesized from chemicals, biologics are produced using advanced biotechnology, making their replication difficult. Biosimilars are nearly identical alternatives to biologics, and they offer a cost-effective option that produces equivalent safety or efficacy outcomes as their reference biologics. Biosimilars are not classified as generic drugs and have a unique regulatory pathway. While biosimilars must demonstrate structural, functional, and clinical similarity to reference biologics, regulatory requirements vary across the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the World Health Organization (WHO). The FDA used to mandate clinical studies for interchangeability status, while the EMA and WHO had more flexible approval pathways that enable broader biosimilar adoption. However, the FDA’s approach is evolving, and they may grant interchangeability with scientific justification without separate switching studies. Regulatory inconsistencies extend beyond biosimilars, as batch-to-batch variability in brand-name biologics does not face the same scrutiny as biosimilar approvals. Addressing these regulatory disparities and greater alignment among the FDA, EMA, and WHO may enhance biosimilar adoption. Acceptance of biosimilars may expand treatment accessibility, reduce healthcare costs, and maintain standards of safety and efficacy in managing musculoskeletal diseases.

Keywords

Biosimilars / biologic medications / biopharmaceuticals / reference products / interchangeability

References

[1] Tóthfalusi L, Endrényi L, Chow S. Statistical and regulatory considerations in assessments of interchangeability of biological drug products. Eur J Health Econ. 2014; 15 Suppl 1: S5-11.

[2] Nowicki M. Basic facts about biosimilars. Kidney Blood Press Res. 2007; 30: 267-72.

[3] Yamauchi P, Crowley J, Kaur P, Spelman L, Warren R. Biosimilars: what the dermatologist should know. J Eur Acad Dermatol Venereol. 2018; 32: 1066-74.

[4] Patel PK, King CR, Feldman SR. Biologics and biosimilars. J Dermatolog Treat. 2015; 26: 299-302.

[5] Patel PV, Purvis CG, Hamid RN, Feldman SR. Biosimilars in dermatology: identifying myths and knowledge gaps. Dermatol Online J. 2023; 29.

[6] FDA Announces Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs [Internet]. U.S. Food and Drug Administration; [cited 2025 Jun 1]. Available from: https://www.fda.gov/news-events/press-announcements/fda-announces-plan-phase-out-animal-testing-requirement-monoclonal-antibodies-and-other-drugs

[7] Quality Considerations in Demonstrating Biosimilarity of a Therapeutic Protein Product to a Reference Product Guidance for Industry [Internet]. U.S. Food and Drug Administration; [cited 2024 Jul 31]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/quality-considerations-demonstrating-biosimilarity-therapeutic-protein-product-reference-product

[8] Biosimilar Regulatory Approval Pathway [Internet]. U.S. Food and Drug Administration; [cited 2025 Jun 28]. Available from: https://www.fda.gov/media/154914/download

[9] Sarnola K, Merikoski M, Jyrkkä J, Hämeen-Anttila K. Physicians’ perceptions of the uptake of biosimilars: a systematic review. BMJ Open. 2020; 10: e034183.

[10] Biosimilar and Interchangeable Biologics: More Treatment Choices [Internet]. US Food and Drug Administration; [cited 2024 Jul 31]. Available from: https://www.fda.gov/consumers/consumer-updates/biosimilar-and-interchangeable-biologics-more-treatment-choices

[11] Purple Book: Database of FDA-Licensed Biological Products [Internet]. U.S. Food and Drug Administration; [cited 2025 Jun 29]. Available from: https://purplebooksearch.fda.gov/

[12] Drugs@FDA: FDA-Approved Drugs [Internet]. U.S. Food and Drug Administration; [cited 2025 Feb 9]. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm

[13] Reyes Neira FA, Bayeh B, Bonfiglioli KR, Aikawa NE, Assad APL, Miossi R, et al. Efficacy of switching from originator adalimumab to biosimilar adalimumab-AACF in patients with axial spondyloarthritis: a 12-month observational study. Explor Musculoskeletal Dis. 2025; 3: 100783.

[14] Biosimilar Medicines: Marketing Authorisation [Internet]. European Medicines Agency (EMA); [cited 2025 Feb 9]. Available from: https://www.ema.europa.eu/en/human-regulatory-overview/marketing-authorisation/biosimilar-medicines-marketing-authorisation

[15] Biosimilar Medicines: Overview [Internet]. European Medicines Agency (EMA); [cited 2025 Feb 9]. Available from: https://www.ema.europa.eu/en/human-regulatory-overview/biosimilar-medicines-overview

[16] Biosimilar Medicines Can Be Interchanged [Internet]. European Medicines Agency (EMA); [cited 2025 Feb 9]. Available from: https://www.ema.europa.eu/en/news/biosimilar-medicines-can-be-interchanged

[17] Machado S, Cruz A, Ferreira PL, Morais C, Pimenta RE. Policy measures and instruments used in European countries to increase biosimilar uptake: a systematic review. Front Public Health. 2024; 12: 1263472.

[18] Download medicine data [Internet]. European Medicines Agency (EMA); [cited 2025 Feb 9]. Available from: https://www.ema.europa.eu/en/medicines/download-medicine-data

[19] Kurki P, Barry S, Bourges I, Tsantili P, Wolff-Holz E. Safety, Immunogenicity and Interchangeability of Biosimilar Monoclonal Antibodies and Fusion Proteins: A Regulatory Perspective. Drugs. 2021; 81: 1881-96.

[20] Guidelines on evaluation of biosimilars [Internet]. World Health Organization; [cited 2025 Feb 9]. Available from: https://www.who.int/publications/m/item/guidelines-on-evaluation-of-biosimilars

[21] Guidelines on the quality, safety and efficacy of biotherapeutic protein products prepared by recombinant DNA technology [Internet]. World Health Organization; [cited 2025 Feb 9]. Available from: https://www.who.int/publications/m/item/recombinant-dna-annex-4-trs-no-987